Skip to Content

Kanuma Approval History

FDA Approved: Yes (First approved December 8, 2015)
Brand name: Kanuma
Generic name: sebelipase alfa
Dosage form: Injection
Company: Alexion Pharmaceuticals, Inc.
Treatment for: Lysosomal Acid Lipase Deficiency

Kanuma (sebelipase alfa) is an enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency (LAL-D).

Development History and FDA Approval Process for Kanuma

Dec  8, 2015Approval FDA Approves Kanuma (sebelipase alfa) for Lysosomal Acid Lipase Deficiency
Sep  6, 2015Alexion Receives Notification of PDUFA Date Extension for Kanuma (sebelipase alfa)
May 21, 2013Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.